Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Telcagepant failure is a headache for Merck (and perhaps Pfizer) but a break for others

This article was originally published in Scrip

Executive Summary

While Merck’s latest job cuts were at the fore of its Q2 update (scripintelligence.com, 1 August 2011), the discontinuation of its promising Phase III acute migraine therapy telcagepant is also notable and will add to the company’s woes. It had been expected to become an important treatment option for migraineurs and compete with the triptan class, the standard of care for the past 20 years. Without telcagepant, the acute migraine market will contract, leaving the prophylactic treatment of migraine as the biggest opportunity for developers.

You may also be interested in...



Biohaven’s Nurtec May Be First Migraine Drug For Acute Treatment And Prevention

Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.

Migraine Drug Atogepant Delivers Good News When Allergan Needs It Most

Oral CGRP inhibitor atogepant delivers strong Phase IIb/III results in episodic migraine prevention less than a week after activist investors went public with their push for a management shakeup to reverse Allergan's falling stock price.

Biohaven Posts Positive Migraine Results, But Investors Are Wary

Biohaven's stock price fell significantly after it reported positive Phase III results for rimegepant in the acute treatment of migraine, but concerns about differences between the company's Phase II and III data eased as potential benefits over Allergan's competing oral CGRP inhibitor emerged.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC013906

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel